Zoetis (ZTS) net income: $2.7B
Zoetis reported a net income of $2.7B for the year ended Dec 31, 2025, up 7.5% from $2.5B a year earlier.
From Zoetis's filings with the SEC · Read the filing · ZTS stock page
Zoetis net income by year
#164 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | $2.7B | +8% |
| Dec 31, 2024 | $2.5B | +6% |
| Dec 31, 2023 | $2.3B | +11% |
| Dec 31, 2022 | $2.1B | +4% |
| Dec 31, 2021 | $2B | – |
Net income of similar companies
Companies in the same industry as Zoetis, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Abbott Laboratories | $6.5B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $4.5B | Dec 31, 2025 |
| AbbVie | $4.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $4B | Dec 31, 2025 |
| Zoetis | $2.7B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $1.4B | Dec 31, 2025 |
| United Therapeutics | $1.3B | Dec 31, 2025 |
Questions and answers
What is Zoetis's net income?
Zoetis reported a net income of $2.7B for the year ended Dec 31, 2025, up 7.5% from $2.5B a year earlier.
Numbers as reported in Zoetis's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology